FDA Brief

Warning letters Drugs

FDA warning letter to

Umendra Life Sciences Private Limited

High riskIssued Jun 2Posted Jun 9Center for Drug Evaluation and Research (CDER)

Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.

What happened

FDA did not inspect; it reviewed records the company sent after FDA's August 14, 2025 request for records under section 704(a)(4) of the FD&C Act. FDA found the quality unit approved talc for use without sound test methods, without asbestos testing that meets the current USP (United States Pharmacopeia, the official drug standard book), and without verifying supplier test results. The company's own identification and asbestos test records did not fully support the results reported.

What FDA found

  1. The quality unit did not make sure drug products were made under CGMP (current good manufacturing practice) and met their specifications.

    21 CFR 211.22
  2. The quality unit accepted talc without test methods and specifications that are scientifically sound and appropriate.

    21 CFR 211.160(b)
  3. Talc tests were not run as the current USP requires, and the identity and asbestos test records did not show the required spectral peaks or a check for serpentine minerals.

    21 CFR 211.160(b)
  4. The talc specifications left out limits for several impurities and some identification procedures.

    21 CFR 211.22
  5. The company did not test each incoming lot of talc for identity and for purity, strength and quality against written specifications.

    21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)
  6. The company relied on supplier certificates of analysis without ever proving those supplier results were reliable, and one certificate appeared to be Indian Pharmacopeia grade rather than USP grade.

    21 CFR 211.84(d)(2)

What FDA wants

FDA tells the company to reply in writing within 15 working days saying what it has fixed and how it will prevent repeat problems, and to send a full quality unit assessment and remediation plan. Separately, FDA asks for talc and finished-product asbestos test results within 30 calendar days and a risk assessment of products still within expiry, which could include customer notices and recalls.

Who should pay attention

  • brands that buy finished OTC drug products from this contract manufacturer
  • companies buying talc-containing drug components from Indian suppliers
  • US importers and distributors of OTC topical drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk